Medtronic's Q3 Profit In Line With Expectation Despite COVID-19 Impact On Procedure Volume

Medtronic Plc's MDT Q3 FY22 sales of $7.76 billion flat year-over-year as reported and an increase of 2% on an organic basis, missing the consensus of $7.90 billion. 

  • The Company's third-quarter revenue results reflect the unfavorable market impact of COVID-19 and health system labor shortages on medical device procedure volumes.
  • Q3 adjusted EPS of $1.37 increased 6.2% from $1.29 a year ago, in line with the analyst consensus.
  • Related: Medtronic Scores Expanded FDA Nod For Cardiac Cryoablation Catheters In Pediatric Patients With Heart Rhythm Condition.
  • Sales at Medtronic's heart devices unit jumped 1% Y/Y (3% organic) to $2.74 billion. 
  • Spine & neurosurgery product segment sales increased 1% (2%) to $2.14 billion.
  • Diabetes revenue of $584 million decreased 7% as reported and 5% organic.
  • The Medical Surgical Portfolio sales decreased 1% (+1% organic) to $2.290 billion. 
  • Guidance: Medtronic expects Q4 FY21 organic revenue growth of approximately 5.5%, in line with current fourth-quarter organic revenue growth Street consensus. 
  • The Q4 revenue would be negatively affected by approximately $185 million.
  • The Company expects Q4 adjusted EPS of $1.56 - $1.58, versus the consensus of $1.58.
  • Price Action: MDT shares are down 0.06% at $100.50 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!